Detalhe da pesquisa
1.
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer.
Br J Cancer
; 129(6): 965-973, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37537253
2.
Genomic correlates of clinical outcome in advanced prostate cancer.
Proc Natl Acad Sci U S A
; 116(23): 11428-11436, 2019 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31061129
3.
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 21(1): 162-174, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31806540
4.
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
N Engl J Med
; 373(18): 1697-708, 2015 Oct 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-26510020
5.
Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.
Radiology
; 283(1): 168-177, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27875103
6.
Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer.
Radiology
; 280(1): 151-60, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26807894
7.
Is there an antiandrogen withdrawal syndrome with enzalutamide?
BJU Int
; 115(3): 373-80, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24906049
8.
Abiraterone and increased survival in metastatic prostate cancer.
N Engl J Med
; 364(21): 1995-2005, 2011 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-21612468
9.
Immunotherapy-Induced Overlap Syndrome: Myositis, Myasthenia Gravis, and Myocarditis-A Case Series.
Case Rep Med
; 2024: 5399073, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38585685
10.
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients.
Cancers (Basel)
; 13(10)2021 May 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34066080
11.
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.
Cancer Discov
; 11(11): 2812-2827, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34045297
12.
Characterizing CDK12-Mutated Prostate Cancers.
Clin Cancer Res
; 27(2): 566-574, 2021 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32988971
13.
Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.
Eur Urol
; 80(2): 243-253, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34103179
14.
HER3 Is an Actionable Target in Advanced Prostate Cancer.
Cancer Res
; 81(24): 6207-6218, 2021 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34753775
15.
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
Eur Urol
; 79(2): 200-211, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33176972
16.
Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer.
Clin Genitourin Cancer
; 18(1): 69-76.e4, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31767448
17.
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis.
Eur Urol Oncol
; 3(2): 176-182, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31307958
18.
Genomics of lethal prostate cancer at diagnosis and castration resistance.
J Clin Invest
; 130(4): 1743-1751, 2020 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31874108
19.
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations.
JAMA Netw Open
; 3(10): e2021692, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33112397
20.
Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.
Eur Urol
; 75(1): 184-192, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30340782